AMF Tjanstepension AB decreased its holdings in Humana Inc. (NYSE:HUM - Free Report) by 81.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,582 shares of the insurance provider's stock after selling 32,469 shares during the quarter. AMF Tjanstepension AB's holdings in Humana were worth $1,924,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Pinnacle Wealth Management Advisory Group LLC lifted its stake in Humana by 3.6% in the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock worth $272,000 after acquiring an additional 37 shares during the period. Atlas Brown Inc. lifted its stake in Humana by 0.6% in the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock worth $1,611,000 after acquiring an additional 38 shares during the period. Moors & Cabot Inc. lifted its stake in Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider's stock worth $519,000 after acquiring an additional 40 shares during the period. Mather Group LLC. lifted its stake in Humana by 21.0% in the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock worth $60,000 after acquiring an additional 41 shares during the period. Finally, Capital Advisors Ltd. LLC lifted its position in Humana by 26.1% during the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock valued at $53,000 after buying an additional 43 shares during the period. Hedge funds and other institutional investors own 92.38% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on HUM shares. Truist Financial raised their price objective on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Morgan Stanley lowered their price objective on Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Barclays raised their price objective on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. lowered their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Twenty analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $285.68.
View Our Latest Analysis on Humana
Insider Buying and Selling at Humana
In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.32% of the company's stock.
Humana Price Performance
NYSE HUM opened at $259.86 on Friday. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The stock has a 50-day moving average of $271.80 and a 200 day moving average of $283.63. The company has a market capitalization of $31.35 billion, a price-to-earnings ratio of 26.12, a PEG ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.
Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current year.
Humana Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.36%. Humana's dividend payout ratio is currently 35.58%.
Humana Profile
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.